A. Memon, Habibun Nisa, Muhammad Osama, Calvin R. Wei
{"title":"Atopic Dermatitis and Abrocitinib: Unraveling the Therapeutic Potential","authors":"A. Memon, Habibun Nisa, Muhammad Osama, Calvin R. Wei","doi":"10.2174/0115743624291067240307051246","DOIUrl":null,"url":null,"abstract":"\n\nAtopic dermatitis (AD) is a chronic immune-mediated skin condition seriously affecting both children and adults and impacting their quality of life. This complex condition involves\ngenetic predisposition, immune system impairment, and environmental factors. The Janus kinase\nsignal transducer and activator of transcription (JAK-STAT) pathway plays a key role in AD\npathogenesis and progression. Abrocitinib presents a hopeful avenue for managing moderate to\nsevere AD, offering significant symptom relief and potential long-term benefits. Its targeted approach to modulating the JAK-STAT pathway holds promise for improved AD management.\nThis comprehensive review explores AD pathogenesis, the chemistry and clinical pharmacology\nof Abrocitinib, and its safety and efficacy in various trials.\n","PeriodicalId":10868,"journal":{"name":"Current Signal Transduction Therapy","volume":"58 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2024-03-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Current Signal Transduction Therapy","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.2174/0115743624291067240307051246","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"Medicine","Score":null,"Total":0}
引用次数: 0
Abstract
Atopic dermatitis (AD) is a chronic immune-mediated skin condition seriously affecting both children and adults and impacting their quality of life. This complex condition involves
genetic predisposition, immune system impairment, and environmental factors. The Janus kinase
signal transducer and activator of transcription (JAK-STAT) pathway plays a key role in AD
pathogenesis and progression. Abrocitinib presents a hopeful avenue for managing moderate to
severe AD, offering significant symptom relief and potential long-term benefits. Its targeted approach to modulating the JAK-STAT pathway holds promise for improved AD management.
This comprehensive review explores AD pathogenesis, the chemistry and clinical pharmacology
of Abrocitinib, and its safety and efficacy in various trials.
特应性皮炎（AD）是一种由免疫介导的慢性皮肤病，严重影响儿童和成年人的生活质量。这种复杂的疾病涉及遗传易感性、免疫系统损伤和环境因素。Janus 激酶信号转导和转录激活因子（JAK-STAT）通路在 AD 的发病和进展过程中起着关键作用。阿罗昔替尼为治疗中度至重度AD提供了一条充满希望的途径，可显著缓解症状并带来潜在的长期益处。本综述探讨了AD的发病机制、阿昔替尼的化学和临床药理，以及它在各种试验中的安全性和有效性。
期刊介绍：
In recent years a breakthrough has occurred in our understanding of the molecular pathomechanisms of human diseases whereby most of our diseases are related to intra and intercellular communication disorders. The concept of signal transduction therapy has got into the front line of modern drug research, and a multidisciplinary approach is being used to identify and treat signaling disorders.
The journal publishes timely in-depth reviews, research article and drug clinical trial studies in the field of signal transduction therapy. Thematic issues are also published to cover selected areas of signal transduction therapy. Coverage of the field includes genomics, proteomics, medicinal chemistry and the relevant diseases involved in signaling e.g. cancer, neurodegenerative and inflammatory diseases. Current Signal Transduction Therapy is an essential journal for all involved in drug design and discovery.
京公网安备 11010802042870号
京ICP备2023020795号-1
分享
求助内容：
应助结果提醒方式：
扫码关注我们
